戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 hich inflammation and immune responses cause vasoocclusive complications in sickle-cell disease.
2 recommended for adults with 3 or more severe vasoocclusive crises during any 12-month period, with SC
3 ther increased during acute sickling events (vasoocclusive crises in humans or hypoxia/reoxygenation
4 ctors that are hypothesized to contribute to vasoocclusive crises in sickle cell anemia are increased
5 ease, and was further reduced during painful vasoocclusive crises to 34% +/- 9% and 25% +/- 3% of con
6 e useful in treating acute painful episodes (vasoocclusive crises) of sickle cell disease (SCD).
7 inely administered to children with frequent vasoocclusive crises.
8 kle cell anemia is characterized by periodic vasoocclusive crises.
9 r sickle cell disease patients vulnerable to vasoocclusive crises.
10 erapeutic intervention for acute sickle cell vasoocclusive crises.
11 re was no difference in isoprostanes between vasoocclusive crisis and patients with sickle cell disea
12 one patient 4 d prior to hospitalization for vasoocclusive crisis contained the highest ET-1 level an
13  findings contribute to the understanding of vasoocclusive crisis in patients with SCD and may have t
14                                          The vasoocclusive crisis is the major clinical feature of si
15  (SpO2) in adult patients with SCD and acute vasoocclusive crisis with simultaneously drawn arterial
16 r treatment of severe pain associated with a vasoocclusive crisis, and use of incentive spirometry in
17 yndrome (pre- and postexchange transfusion), vasoocclusive crisis, and/or at baseline; 12 normal volu
18 ve spirometry in patients hospitalized for a vasoocclusive crisis.
19 function, hemostasis, response to injury and vasoocclusive disease, and to test the prevailing hypoth
20 eviously linked to vascular inflammation and vasoocclusive disease.
21                          Degos' disease is a vasoocclusive disorder involving the cutaneous and gastr
22                                          For vasoocclusive episode (VOE), GWAS detected multiple sign
23 initiation, progression, and resolution of a vasoocclusive episode may present features of ischemia-r
24 n (BCAM/Lu) receptor, which is implicated in vasoocclusive episodes in sickle cell disease and activa
25 s may lead to novel antiadhesive targets for vasoocclusive episodes in sickle cell disease.
26 nude and humanized SCD mouse models of acute vasoocclusive episodes using intravital microscopy.
27 ive in sickle patients presenting with acute vasoocclusive episodes, and only 10+/-13% positive in no
28 e cell disease (SCD), treatment of recurrent vasoocclusive episodes, leading to pain crises and organ
29 s greater when sickle patients develop acute vasoocclusive episodes.
30 gical, and hematological factors involved in vasoocclusive events associated with SCD and to develop
31 electin inhibition has been shown to prevent vasoocclusive events in patients with SCD; however, the
32 to the pathology of thrombotic disorders and vasoocclusive events in sickle cell disease.
33 olymerization of Hb S promotes hemolysis and vasoocclusive events in the microvasculature of patients
34 kocyte-endothelium interaction contribute to vasoocclusive events in the sickle mice and perhaps in h
35 o evoke, control, and inhibit the collective vasoocclusive or jamming event in sickle cell disease.
36 nary hemodynamics during sickle cell disease vasoocclusive pain and ACS.Clinical trial registered wit
37 phy are often encountered during sickle cell vasoocclusive pain and acute chest syndrome (ACS).
38          In patients with moderate to severe vasoocclusive pain, RheothRx was safe and may offer a th
39 abnormal RBC vasoactivity contributes to the vasoocclusive pathophysiology of sickle cell anemia, and
40                                          The vasoocclusive process in patients with sickle cell disea